<code id='59FA53D965'></code><style id='59FA53D965'></style>
    • <acronym id='59FA53D965'></acronym>
      <center id='59FA53D965'><center id='59FA53D965'><tfoot id='59FA53D965'></tfoot></center><abbr id='59FA53D965'><dir id='59FA53D965'><tfoot id='59FA53D965'></tfoot><noframes id='59FA53D965'>

    • <optgroup id='59FA53D965'><strike id='59FA53D965'><sup id='59FA53D965'></sup></strike><code id='59FA53D965'></code></optgroup>
        1. <b id='59FA53D965'><label id='59FA53D965'><select id='59FA53D965'><dt id='59FA53D965'><span id='59FA53D965'></span></dt></select></label></b><u id='59FA53D965'></u>
          <i id='59FA53D965'><strike id='59FA53D965'><tt id='59FA53D965'><pre id='59FA53D965'></pre></tt></strike></i>

          focus

          focus

          author:hotspot    Page View:986
          Dr. Laurie Glimcher, CEO of Dana Farber Cancer Institute, opens both arms while talking — coverage from STAT
          Laurie Glimcher, CEO of Dana Farber Cancer Institute, is the architect of the biggest shakeup in Boston health care in decades. David L. Ryan/Globe Staff

          Dr. Laurie Glimcher learned early on from her father, a prominent physician-researcher, that success in science was built on a basic principle: Big discoveries require big risks.

          The younger Glimcher took that advice to heart. In the late 1990s at her Harvard immunology lab, Glimcher and her postdoctoral student began a series of experiments that colleagues deemed “crazy.” But after a year of trial and error, the lab had a eureka moment when it found that white blood cells could be reprogrammed, a seminal discovery that led to new ways to treat cancer.

          advertisement

          “Most scientists do good work, but they don’t transform a scientific question,” said Glimcher. “I always felt the only way to do that is to think big and go after something that’s going to be really important.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end
          Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

          1:29FILE-AsignbearingthecompanylogooutsideaTeslastoreinCherryCreekMallinDenverisseenhereonFeb.9,2019

          read more
          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more

          Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

          1:29FILE-ThiscombooffileimagesshowsFacebookCEOMarkZuckerberg,left,andTeslaandSpaceXCEOElonMusk.ElonM